Wells Fargo & Company MN Sells 886,220 Shares of Hologic, Inc. (HOLX)

Wells Fargo & Company MN reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 24.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,699,042 shares of the medical equipment provider’s stock after selling 886,220 shares during the period. Wells Fargo & Company MN owned about 0.99% of Hologic worth $110,606,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Reilly Financial Advisors LLC grew its holdings in Hologic by 3.7% during the 3rd quarter. Reilly Financial Advisors LLC now owns 39,430 shares of the medical equipment provider’s stock worth $1,616,000 after acquiring an additional 1,390 shares in the last quarter. Sentry Investment Management LLC grew its holdings in Hologic by 8.3% during the 2nd quarter. Sentry Investment Management LLC now owns 18,271 shares of the medical equipment provider’s stock worth $726,000 after acquiring an additional 1,394 shares in the last quarter. CIBC Asset Management Inc boosted its holdings in shares of Hologic by 4.1% in the 2nd quarter. CIBC Asset Management Inc now owns 38,603 shares of the medical equipment provider’s stock valued at $1,534,000 after buying an additional 1,504 shares in the last quarter. Majedie Asset Management Ltd boosted its holdings in shares of Hologic by 1.5% in the 3rd quarter. Majedie Asset Management Ltd now owns 105,302 shares of the medical equipment provider’s stock valued at $4,315,000 after buying an additional 1,589 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its holdings in shares of Hologic by 0.4% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 412,544 shares of the medical equipment provider’s stock valued at $16,906,000 after buying an additional 1,600 shares in the last quarter. 97.62% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have recently issued reports on HOLX shares. TheStreet upgraded shares of Hologic from a “c” rating to a “b” rating in a report on Tuesday, July 31st. BTIG Research restated a “buy” rating and issued a $47.00 target price on shares of Hologic in a report on Thursday, August 2nd. Deutsche Bank upped their target price on shares of Hologic from $42.00 to $45.00 and gave the company a “hold” rating in a report on Wednesday, August 1st. UBS Group started coverage on shares of Hologic in a report on Tuesday, October 9th. They issued a “neutral” rating and a $44.00 target price for the company. Finally, Zacks Investment Research cut shares of Hologic from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. Eleven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $44.41.

Shares of NASDAQ:HOLX opened at $40.97 on Tuesday. The firm has a market cap of $11.37 billion, a P/E ratio of 18.37, a price-to-earnings-growth ratio of 1.88 and a beta of 0.65. The company has a quick ratio of 0.95, a current ratio of 1.23 and a debt-to-equity ratio of 1.11. Hologic, Inc. has a 1-year low of $35.10 and a 1-year high of $45.09.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, November 7th. The medical equipment provider reported $0.58 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.59 by ($0.01). The business had revenue of $813.50 million for the quarter, compared to analyst estimates of $808.63 million. Hologic had a positive return on equity of 23.52% and a negative net margin of 3.46%. The firm’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.50 EPS. As a group, research analysts expect that Hologic, Inc. will post 2.4 earnings per share for the current fiscal year.

In related news, Director Christiana Stamoulis sold 30,967 shares of the stock in a transaction on Tuesday, October 2nd. The shares were sold at an average price of $40.70, for a total transaction of $1,260,356.90. Following the completion of the sale, the director now owns 66,006 shares in the company, valued at approximately $2,686,444.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Benjamin Jordan Cohn sold 3,437 shares of the stock in a transaction on Wednesday, September 19th. The stock was sold at an average price of $41.50, for a total transaction of $142,635.50. Following the sale, the insider now owns 16,520 shares of the company’s stock, valued at approximately $685,580. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,519 shares of company stock valued at $2,003,965. 0.88% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.wkrb13.com/2018/11/13/wells-fargo-company-mn-sells-886220-shares-of-hologic-inc-holx.html.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

See Also: What is dollar cost averaging (DCA)?

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply